These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1028 related items for PubMed ID: 21991951

  • 1. Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
    O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS, TEMSO Trial Group.
    N Engl J Med; 2011 Oct 06; 365(14):1293-303. PubMed ID: 21991951
    [Abstract] [Full Text] [Related]

  • 2. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L, TOWER Trial Group.
    Lancet Neurol; 2014 Mar 06; 13(3):247-56. PubMed ID: 24461574
    [Abstract] [Full Text] [Related]

  • 3. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
    [Abstract] [Full Text] [Related]

  • 4. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
    Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT, DEFINE Study Investigators.
    N Engl J Med; 2012 Sep 20; 367(12):1098-107. PubMed ID: 22992073
    [Abstract] [Full Text] [Related]

  • 5. Teriflunomide for multiple sclerosis.
    He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.
    Cochrane Database Syst Rev; 2016 Mar 22; 3(3):CD009882. PubMed ID: 27003123
    [Abstract] [Full Text] [Related]

  • 6. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
    Miller AE.
    Clin Ther; 2015 Oct 01; 37(10):2366-80. PubMed ID: 26365096
    [Abstract] [Full Text] [Related]

  • 7. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
    Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ, CLARITY Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):416-26. PubMed ID: 20089960
    [Abstract] [Full Text] [Related]

  • 8. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):402-15. PubMed ID: 20089954
    [Abstract] [Full Text] [Related]

  • 9. Placebo-controlled trial of oral laquinimod for multiple sclerosis.
    Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M, ALLEGRO Study Group.
    N Engl J Med; 2012 Mar 15; 366(11):1000-9. PubMed ID: 22417253
    [Abstract] [Full Text] [Related]

  • 10. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.
    Wolinsky JS, Narayana PA, Nelson F, Datta S, O'Connor P, Confavreux C, Comi G, Kappos L, Olsson TP, Truffinet P, Wang L, Miller A, Freedman MS, Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group.
    Mult Scler; 2013 Sep 15; 19(10):1310-9. PubMed ID: 23447359
    [Abstract] [Full Text] [Related]

  • 11. Teriflunomide for multiple sclerosis.
    He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S.
    Cochrane Database Syst Rev; 2012 Dec 12; 12():CD009882. PubMed ID: 23235682
    [Abstract] [Full Text] [Related]

  • 12. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
    O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R, Teriflunomide Multiple Sclerosis Trial Group, University of British Columbia MS/MRI Research Group.
    Neurology; 2006 Mar 28; 66(6):894-900. PubMed ID: 16567708
    [Abstract] [Full Text] [Related]

  • 13. Ofatumumab versus Teriflunomide in Multiple Sclerosis.
    Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L, ASCLEPIOS I and ASCLEPIOS II Trial Groups.
    N Engl J Med; 2020 Aug 06; 383(6):546-557. PubMed ID: 32757523
    [Abstract] [Full Text] [Related]

  • 14. Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial.
    Freedman MS, Wolinsky JS, Wamil B, Confavreux C, Comi G, Kappos L, Olsson TP, Miller A, Benzerdjeb H, Li H, Simonson C, O'Connor PW, Teriflunomide Multiple Sclerosis Trial Group and the MRI Analysis Center.
    Neurology; 2012 Jun 05; 78(23):1877-85. PubMed ID: 22622860
    [Abstract] [Full Text] [Related]

  • 15. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
    Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdová EK, Hennessy B, Hohlfeld R, Lublin F, Montalban X, Pozzilli C, Scherz T, D'Ambrosio D, Linscheid P, Vaclavkova A, Pirozek-Lawniczek M, Kracker H, Sprenger T.
    JAMA Neurol; 2021 May 01; 78(5):558-567. PubMed ID: 33779698
    [Abstract] [Full Text] [Related]

  • 16. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
    Mult Scler; 2010 Jul 01; 16(7):848-54. PubMed ID: 20488825
    [Abstract] [Full Text] [Related]

  • 17. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CONFIRM Study Investigators.
    N Engl J Med; 2012 Sep 20; 367(12):1087-97. PubMed ID: 22992072
    [Abstract] [Full Text] [Related]

  • 18. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS, Montalban X, Miller AE, Dive-Pouletty C, Hass S, Thangavelu K, Leist TP.
    Mult Scler Relat Disord; 2016 Nov 20; 10():204-212. PubMed ID: 27919491
    [Abstract] [Full Text] [Related]

  • 19. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
    N Engl J Med; 2006 Mar 02; 354(9):911-23. PubMed ID: 16510745
    [Abstract] [Full Text] [Related]

  • 20. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
    Brunetti L, Wagner ML, Maroney M, Ryan M.
    Ann Pharmacother; 2013 Sep 02; 47(9):1153-60. PubMed ID: 24259730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.